PRESS RELEASE – New Publication on LB Rhamnosus PB01

PRESS RELEASE – New Publication on LB Rhamnosus PB01

FOR IMMEDIATE RELASE.

Copenhagen, Denmark, December 12th 2016 – Bifodan A/S is pleased to announce the publication of new and promising scientific evidence on its proprietary strain, Lactobacillus Rhamnosus PB01, and its potential effect on pain management.

This study, titled “A Potential Nociceptive Regulatory Effect of Lactobacillus Rhamnosus PB01 (DSM 14870) On Mechanical Sensitivity In Diet-Induced Obesity Model” was recently published in ‘Pain Research and Management’. The research was performed in collaboration with Aalborg University in Denmark and concludes that, when placed on a Lactobacillus rhamnosus PB01 supplemented diet, diet-induced, obese mice demonstrate a lower sensitivity to mechanical stimulation; a strong indication that this specific strain, may have potential to reduce the experience of pain.

‘Regardless of the underlying mechanism, Lactobacillus Rhamnosus PB01 can be suggested as a candidate for a novel therapeutic strategy in pain management of obese and normal weight individuals’ author of the study, Dr. Feresteh Dardmeh from University of Aalborg.

Chief Scientific Officer at Bifodan, Erik Brandsborg continues: ’Credible research is the strength behind our proprietary strains. Our systematic screening of Lactobacillus Rhamnosus PB01 continues to reveal new strain specific capabilities, which we are excited to explore further together with our scientific partners around the world. Translating such findings into human application is one of our core competencies.’

To obtain a copy of our latest publication or to learn more about the scientific research already carried out with PB01, please contact us at sab@bifodan.com.

For further information please contact:
Mr. Steen Andersen, President & CEO Bifodan A/S
Phone: +45 3163 7901
E-mail: sta@bifodan.com

Mrs. Susanne Baekgaard, Vice President Marketing Bifodan A/S
Phone: +45 3163 7918
E-mail: sab@bifodan.com

Download as PDF

 

Bifodan A/S develops and manufactures probiotic turnkey solutions for private label customers worldwide. Based just North of Copenhagen, Denmark, Bifodan delivers clinically documented, high quality probiotic products, manufactured at our GMP approved production facility. Bifodan has a long history in probiotic bacteria, as the company was founded by the first Danish dairy to isolate the lactobacillus acidophilus bacteria in 1938. Bifodan has been dedicated to research and development of probiotic nutritional supplements since 1992.

DISCLAIMER

This section is intended for B2B purposes. Please check the box if applicable.

No, I am a private consumer